| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Departments of Neurology (Drs. Zabetian and Samii and D. Yearout), Medicine (Dr. Raskind), and Psychiatry and Behavioral Sciences (Dr. Raskind), University of Washington School of Medicine, Seattle; Geriatric (Dr. Zabetian and D. Yearout), Northwest Parkinson’s Disease (Dr. Samii), and Mental Illness Research Education and Clinical Centers (Dr. Raskind), Veterans Affairs Puget Sound Health Care System, Seattle; Virginia Mason Medical Center (Dr. Roberts), Seattle; and Booth Gardner Parkinson’s Care Center (Drs. Mosley, Leis, and Griffith), Evergreen Hospital Medical Center, Kirkland, WA.
address correspondence and reprint requests to Dr. Zabetian, Geriatric Research Education and Clinical Center S-182, VA Puget Sound Health Care System, 1660 South Columbian Way, Seattle, WA 98108; e-mail: zabetian{at}u.washington.edu
Referral-based studies indicate that a mutation (G2019S) in exon 41 of the LRRK2 gene might be a common cause of Parkinson disease (PD). The authors sequenced leucine-rich repeat kinase 2 (LRRK2) exons 31, 35, and 41 in 371 consecutively recruited patients with PD and found mutations in six (1.6%) subjects, including two heterozygous for new putative pathogenic variants (R1441H, IVS31 + 3A
G). These data confirm the important contribution of LRRK2 to PD susceptibility in a clinic-based population.
Editorial, see page 664
See also pages 696 and 738
This article was previously published in electronic format as an Expedited E-Pub on June 29, 2005, at www.neurology.org.
Supported by the Geriatric and Mental Illness Research Education and Clinical Centers, VA Puget Sound Health Care System, and grants from the National Institutes of Health (K08-NS44138) and Parkinson’s Disease Foundation (C.P.Z.).
Received April 4, 2005. Accepted in final form May 23, 2005.
Please
This article has been cited by other articles:
|
|
 |
|
  Y. Tong, A. Pisani, G. Martella, M. Karouani, H. Yamaguchi, E. N. Pothos, and J. Shen R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice PNAS, August 25, 2009; 106(34): 14622 - 14627. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Klein and M. G. Schlossmacher Parkinson disease, 10 years after its genetic revolution: Multiple clues to a complex disorder Neurology, November 27, 2007; 69(22): 2093 - 2104. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. C. Nichols, V. E. Elsaesser, N. Pankratz, M. W. Pauciulo, D. K. Marek, C. A. Halter, A. Rudolph, C. W. Shults, T. Foroud, and For the Parkinson Study Group PROGENI Investigato LRRK2 mutation analysis in Parkinson disease families with evidence of linkage to PARK8 Neurology, October 30, 2007; 69(18): 1737 - 1744. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Orr-Urtreger, C. Shifrin, U. Rozovski, S. Rosner, D. Bercovich, T. Gurevich, H. Yagev-More, A. Bar-Shira, and N. Giladi The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: Is there a gender effect? Neurology, October 16, 2007; 69(16): 1595 - 1602. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Luzon-Toro, E. R. de la Torre, A. Delgado, J. Perez-Tur, and S. Hilfiker Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation Hum. Mol. Genet., September 1, 2007; 16(17): 2031 - 2039. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. H. V. Schapira The Importance of LRRK2 Mutations in Parkinson Disease. Arch Neurol, September 1, 2006; 63(9): 1225 - 1228. [Full Text] [PDF]
|
|
|
|
|
|
E.-K. Tan and J. Jankovic Genetic testing in Parkinson disease: promises and pitfalls. Arch Neurol, September 1, 2006; 63(9): 1232 - 1237. [Full Text] [PDF]
|
|
|
|
|
|
L. Ishihara, L. Warren, R. Gibson, R. Amouri, S. Lesage, A. Durr, M. Tazir, Z. K. Wszolek, R. J. Uitti, W. C. Nichols, et al. Clinical Features of Parkinson Disease Patients With Homozygous Leucine-Rich Repeat Kinase 2 G2019S Mutations. Arch Neurol, September 1, 2006; 63(9): 1250 - 1254. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. P. Zabetian, H. Morino, H. Ujike, M. Yamamoto, M. Oda, H. Maruyama, Y. Izumi, R. Kaji, A. Griffith, B. C. Leis, et al. Identification and haplotype analysis of LRRK2 G2019S in Japanese patients with Parkinson disease Neurology, August 22, 2006; 67(4): 697 - 699. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. H.V. Schapira Etiology of Parkinson's disease Neurology, May 23, 2006; 66(10_suppl_4): S10 - S23. [Abstract] [Full Text]
|
|
|
|
 |
|
 C H Williams-Gray, A Goris, T Foltynie, J Brown, M Maranian, A Walton, D A S Compston, S J Sawcer, and R A Barker Prevalence of the LRRK2 G2019S mutation in a UK community based idiopathic Parkinson's disease cohort J. Neurol. Neurosurg. Psychiatry, May 1, 2006; 77(5): 665 - 667. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Gaig, M. Ezquerra, M. J. Marti, E. Munoz, F. Valldeoriola, and E. Tolosa LRRK2 Mutations in Spanish Patients With Parkinson Disease: Frequency, Clinical Features, and Incomplete Penetrance. Arch Neurol, March 1, 2006; 63(3): 377 - 382. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Gloeckner, N. Kinkl, A. Schumacher, R. J. Braun, E. O'Neill, T. Meitinger, W. Kolch, H. Prokisch, and M. Ueffing The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity Hum. Mol. Genet., January 15, 2006; 15(2): 223 - 232. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Brice Genetics of Parkinson's disease: LRRK2 on the rise Brain, December 1, 2005; 128(12): 2760 - 2762. [Full Text] [PDF]
|
|
|
|
|
|
A. B. West, D. J. Moore, S. Biskup, A. Bugayenko, W. W. Smith, C. A. Ross, V. L. Dawson, and T. M. Dawson From The Cover: Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity PNAS, November 15, 2005; 102(46): 16842 - 16847. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Foroud LRRK2: Both a cause and a risk factor for Parkinson disease? Neurology, September 13, 2005; 65(5): 664 - 665. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
